Journal: Oncology Reports

Article Title: Unravelling heterogeneous effects of cancer‑associated fibroblasts on poor prognosis markers in breast cancer EM‑G3 cell line: In vitro ‑targeted treatment (anti‑IL-6, anti‑VEGF-A, anti‑MFGE8) based on transcriptomic profiling

doi: 10.3892/or.2023.8662

Figure Lengend Snippet: Reagents used for western blot staining of cells.

Article Snippet: TWIST1 , Rabbit , IgG , Monoclonal , 1:1,000 , 69366 , Cell Signaling Technology, Inc..

Techniques: Western Blot, Staining, Produced

Journal: Oncology Reports

Article Title: Unravelling heterogeneous effects of cancer‑associated fibroblasts on poor prognosis markers in breast cancer EM‑G3 cell line: In vitro ‑targeted treatment (anti‑IL-6, anti‑VEGF-A, anti‑MFGE8) based on transcriptomic profiling

doi: 10.3892/or.2023.8662

Figure Lengend Snippet: Western blot analysis of EM-G3 cells. Protein expression analysis in indirect (CM) co-culture of EM-G3 cells with HDFs, BCCFs, SCCFs and BCMFs. The studied conditions for each studied fibroblast type included: Control culture of EM-G3 cells, EM-G3 cells cultured in CM derived from respective fibroblasts, EM-G3 cells cultured in CM enriched with neutralizing antibodies against either IL-6 or VEGF-A or MFGE8 or combination of all three tested antibodies (anti-IL-6 + anti-VEGF-A + anti-MFGE8). The expression profile of the following markers related to cell differentiation and epithelial-to-mesenchymal transition was evaluated: keratin-8, keratin-14, keratin-18, keratin-19, vimentin, SLUG, SNAIL, TWIST1, ZEB1, E-cadherin, N-cadherin, VE-cadherin. β-Actin was used as sample loading control (representative beta-actin controls are shown). HDFs, human dermal fibroblasts; BCCFs, basal cell carcinoma fibroblasts; SCCFs, squamous cell carcinoma fibroblasts; BCMFs, breast cancer metastasis fibroblasts; CM, conditioned media.

Article Snippet: TWIST1 , Rabbit , IgG , Monoclonal , 1:1,000 , 69366 , Cell Signaling Technology, Inc..

Techniques: Western Blot, Expressing, Co-Culture Assay, Control, Cell Culture, Derivative Assay, Cell Differentiation

Journal: Biochemistry and Biophysics Reports

Article Title: High expression of THY1 is a prognostic marker for gastric Cancer: Deciphering its transcriptional regulation as a component of the Epithelial–mesenchymal transition

doi: 10.1016/j.bbrep.2025.102050

Figure Lengend Snippet: Conservation of PRRX1, TWIST1, and SNAI2 binding sites in THY1 regulatory regions. The figure shows the location and conservation of transcription factor binding sites within the THY1 regulatory regions for PRRX1 (A) , TWIST1 (B) , and SNAI2 (C) . At the top of each panel, a schematic representation of the THY1 gene is shown, where +1 marks the transcription start site, and the 3-kb upstream region is defined as the promoter. The first intron begins after the end of exon 1 (+60). Binding sites are labeled with their respective names, and their positions relative to the transcription start site are indicated. Below each schematic, alignment tables show the conservation of binding sites across the evaluated species. Conserved nucleotides are highlighted in gray, whereas nonconserved nucleotides are highlighted in white. The species names are listed on the left, and the nucleotide positions relative to the human sequence are shown above each alignment. The schematics of the gene structure, regulatory regions, and binding site positions are illustrative and not drawn to scale.

Article Snippet: Briefly, chromatin from the HGC-27, AGS, and KATO III cell lines—which was previously prepared and digested with micrococcal nuclease—was incubated with 2 μg of either a TWIST1 antibody (sc-81417, Santa Cruz Biotechnology, TX, USA), a PRRX1 antibody (sc-293386, Santa Cruz Biotechnology, TX, USA), a SNAI2 antibody (#9585, Cell Signaling Technology, MA, USA) or a negative immunoprecipitation control consisting of a normal anti-IgG rabbit antibody (#2729, Cell Signaling Technology, MA, USA).

Techniques: Binding Assay, Labeling, Sequencing

Journal: Biochemistry and Biophysics Reports

Article Title: High expression of THY1 is a prognostic marker for gastric Cancer: Deciphering its transcriptional regulation as a component of the Epithelial–mesenchymal transition

doi: 10.1016/j.bbrep.2025.102050

Figure Lengend Snippet: Chromatin immunoprecipitation analysis of PRRX1, TWIST1 and SNAI2 binding sites in THY1 regulatory regions across gastric cancer cell lines. The bar graphs represent the bound/input (%) values for each binding site evaluated. The y-axis indicates the percentage of DNA recovered (bound) relative to the input DNA, and the x-axis shows the cell lines analyzed: HGC-27 ( THY1 high ), Kato III, and AGS (both THY1 low ). The title of each panel specifies the transcription factor, the binding site name, and its position within the THY1 regulatory regions. (A – C) correspond to PRRX1 binding sites, (D – H) correspond to TWIST1 binding sites, and (I – L) correspond to SNAI2 binding sites. The error bars represent the standard deviations of three replicates. Statistical significance was determined using pairwise Mann‒Whitney U tests with p value correction. For each bound/input (%) analysis, the bound/input (%) value of the control IgG was subtracted from the value of each cell line. The data are shown as the means ± standard deviations. ns: not significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.

Article Snippet: Briefly, chromatin from the HGC-27, AGS, and KATO III cell lines—which was previously prepared and digested with micrococcal nuclease—was incubated with 2 μg of either a TWIST1 antibody (sc-81417, Santa Cruz Biotechnology, TX, USA), a PRRX1 antibody (sc-293386, Santa Cruz Biotechnology, TX, USA), a SNAI2 antibody (#9585, Cell Signaling Technology, MA, USA) or a negative immunoprecipitation control consisting of a normal anti-IgG rabbit antibody (#2729, Cell Signaling Technology, MA, USA).

Techniques: Chromatin Immunoprecipitation, Binding Assay, Control